Peter B Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4440509/publications.pdf

Version: 2024-02-01

		117625	102487
129	4,973	34	66
papers	citations	h-index	g-index
131	131	131	7337
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64.	0.6	3
2	Novel biallelic variants expand the SLC5A6-related phenotypic spectrum. European Journal of Human Genetics, 2022, 30, 439-449.	2.8	10
3	Clinical, electrophysiological, and imaging findings in childhood brachial plexus injury. Developmental Medicine and Child Neurology, 2022, , .	2.1	5
4	Diagnostic capabilities of nanopore longâ€read sequencing in muscular dystrophy. Annals of Clinical and Translational Neurology, 2022, 9, 1302-1309.	3.7	10
5	Megf10 deficiency impairs skeletal muscle stem cell migration and muscle regeneration. FEBS Open Bio, 2021, 11, 114-123.	2.3	8
6	Growth charts in Cockayne syndrome type 1 and type 2. European Journal of Medical Genetics, 2021, 64, 104105.	1.3	4
7	Hunting for the perfect test: Neuromuscular diagnosis in the age of genomic bounty. Muscle and Nerve, 2021, 63, 282-284.	2.2	1
8	POLRMT mutations impair mitochondrial transcription causing neurological disease. Nature Communications, 2021, 12, 1135.	12.8	21
9	<scp>hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies. Muscle and Nerve, 2021, 63, 928-940.</scp>	2.2	7
10	A form of muscular dystrophy associated with pathogenic variants in JAG2. American Journal of Human Genetics, 2021, 108, 840-856.	6.2	15
11	Phenotypic implications of pathogenic variant types in Pompe disease. Journal of Human Genetics, 2021, 66, 1089-1099.	2.3	6
12	An Opportune Time for Newborn Screening in Duchenne Muscular Dystrophy. JAMA Neurology, 2021, 78, 901.	9.0	7
13	The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy. Pediatric Neurology, 2020, 102, 1-2.	2.1	1
14	Utility and practice of electrodiagnostic testing in the pediatric population: An AANEM consensus statement. Muscle and Nerve, 2020, 61, 143-155.	2.2	14
15	Child neurology in the 21st century. Neurology, 2020, 94, 75-82.	1.1	15
16	Emeryâ€Dreifuss muscular dystrophy. Muscle and Nerve, 2020, 61, 436-448.	2.2	84
17	The ties that bind: functional clusters in limb-girdle muscular dystrophy. Skeletal Muscle, 2020, 10, 22.	4.2	17
18	Ethical decision-making for children with neuromuscular disorders in the COVID-19 crisis. Neurology, 2020, 95, 260-265.	1.1	7

#	Article	IF	Citations
19	Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Pediatric Neurology, 2020, 111, 40-43.	2.1	7
20	Neuromuscular Transmission Disorders. , 2020, , 1257-1279.		1
21	Hereditary and Acquired Myopathies. , 2020, , 1281-1349.		1
22	AAV-MediatedTAZGene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome. Human Gene Therapy, 2019, 30, 139-154.	2.7	40
23	Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-TAZ Gene Delivery. International Journal of Molecular Sciences, 2019, 20, 3416.	4.1	9
24	Neurodevelopmental outcomes at 9–14Âmonths gestational age after treatment of neonatal seizures due to brain injury. Child's Nervous System, 2019, 35, 1571-1578.	1.1	4
25	Identification of a pathogenic mutation in ATP2A1 via in silico analysis of exome data for cryptic aberrant splice sites. Molecular Genetics & Enomic Medicine, 2019, 7, e552.	1.2	9
26	Intravenous Immunoglobulin as a Therapeutic Option for Mycoplasma pneumoniae Encephalitis. Journal of Child Neurology, 2019, 34, 687-691.	1.4	8
27	AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome. Molecular Therapy - Methods and Clinical Development, 2019, 13, 167-179.	4.1	17
28	Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy. Human Molecular Genetics, 2019, 28, 2365-2377.	2.9	7
29	The impact of Megf10/Drpr gainâ€ofâ€function on muscle development inÂ <i>Drosophila</i> . FEBS Letters, 2019, 593, 680-696.	2.8	5
30	Lumbosacral ventral spinal nerve root atrophy identified on MRI in a case of spinal muscular atrophy type II. Clinical Imaging, 2019, 53, 134-137.	1.5	2
31	Electrophysiologic Features of Radial Neuropathy in Childhood and Adolescence. Pediatric Neurology, 2018, 81, 14-18.	2.1	5
32	Impact of PYROXD1 deficiency on cellular respiration and correlations with genetic analyses of limb-girdle muscular dystrophy in Saudi Arabia and Sudan. Physiological Genomics, 2018, 50, 929-939.	2.3	15
33	Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy. American Journal of Human Genetics, 2018, 102, 858-873.	6.2	65
34	Dollars and antisense for Duchenne muscular dystrophy. Neurology, 2018, 90, 1091-1092.	1.1	5
35	Electrophysiologic features of ulnar neuropathy in childhood and adolescence. Clinical Neurophysiology, 2017, 128, 751-755.	1.5	4
36	The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatric Surgery International, 2017, 33, 683-694.	1.4	26

#	Article	IF	CITATIONS
37	Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Science Translational Medicine, 2017, 9, .	12.4	516
38	Consequences of MEGF10 deficiency on myoblast function and Notch1 interactions. Human Molecular Genetics, 2017, 26, 2984-3000.	2.9	30
39	Child Neurology Recruitment and Training: Views of Residents and Child Neurologists From the 2015 AAP/CNS Workforce Survey. Pediatric Neurology, 2017, 66, 89-95.	2.1	15
40	The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. Journal of Human Genetics, 2017, 62, 243-252.	2.3	73
41	Electrophysiologic features of fibular neuropathy in childhood and adolescence. Muscle and Nerve, 2017, 55, 693-697.	2.2	11
42	Laboratory Assessment of the Child with Suspected Neuromuscular Disorders. , 2017, , 1038-1043.		0
43	Approach to Electrodiagnostic Testing in Children. , 2017, , 23-27.		1
44	Motor Unit Number Estimation., 2017,, 151-155.		0
45	Muscle Analysis. , 2017, , 115-121.		0
46	Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle and Nerve, 2016, 54, 681-689.	2.2	29
47	Homozygous nonsense mutation in <i>SGCA</i> iis a common cause of limb-girdle muscular dystrophy in Assiut, Egypt. Muscle and Nerve, 2016, 54, 690-695.	2.2	12
48	Neuropathic and Myopathic Pain. Seminars in Pediatric Neurology, 2016, 23, 242-247.	2.0	3
49	The child neurology clinical workforce in 2015. Neurology, 2016, 87, 1384-1392.	1.1	49
50	Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. Journal of Pediatrics, 2016, 178, 227-232.	1.8	12
51	Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. Muscle and Nerve, 2016, 54, 997-1006.	2.2	4
52	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. Journal of Clinical Investigation, 2016, 126, 4219-4236.	8.2	56
53	Outcome reliability in nonâ€Ambulatory Boys/Men with duchenne muscular dystrophy. Muscle and Nerve, 2015, 51, 522-532.	2.2	60
54	A slowly progressive form of limbâ€girdle muscular dystrophy type 2C associated with founder mutation in the <i>SGCG</i> gene in Puerto Rican Hispanics. Molecular Genetics & Denomic Medicine, 2015, 3, 92-98.	1.2	10

#	Article	IF	Citations
55	PLIN2 inhibits insulin-induced glucose uptake in myoblasts through the activation of the NLRP3 inflammasome. International Journal of Molecular Medicine, 2015, 36, 839-844.	4.0	36
56	Expanding the Phenotypic Spectrum and Variability of Endocrine Abnormalities Associated With TUBB3 E410K Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E473-E477.	3.6	21
57	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology, 2015, 84, 1369-1378.	1.1	88
58	Electromyography in Pediatrics., 2015,, 32-45.		0
59	Chronic Inflammatory Demyelinating Polyradiculoneuropathy. , 2015, , 398-417.		1
60	Advances in Muscular Dystrophies. JAMA Neurology, 2015, 72, 741.	9.0	23
61	Juvenile and Neonatal Myasthenia Gravis. , 2015, , 482-496.		1
62	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Department of the Neuroman of Neuroman	1.1	3
63	Modeling Human MEGF10 Myopathy in Drosophila melanogaster. FASEB Journal, 2015, 29, 613.9.	0.5	О
64	Referral and diagnostic trends in pediatric electromyography in the molecular era. Muscle and Nerve, 2014, 50, 244-249.	2.2	17
65	Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing. Clinical Epigenetics, 2014, 6, 23.	4.1	61
66	POMK mutations disrupt muscle development leading to a spectrum of neuromuscular presentations. Human Molecular Genetics, 2014, 23, 5781-5792.	2.9	72
67	Comparison of Plasmapheresis and Intravenous Immunoglobulin as Maintenance Therapies for Juvenile Myasthenia Gravis. JAMA Neurology, 2014, 71, 575.	9.0	64
68	MicroRNA-486–dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy–associated symptoms. Journal of Clinical Investigation, 2014, 124, 2651-2667.	8.2	128
69	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in <i>TPM2</i> and <i>TPM3</i> causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	2.5	92
70	The motor neuron response to <i>SMN1</i> deficiency in spinal muscular atrophy. Muscle and Nerve, 2014, 49, 636-644.	2.2	34
71	Silencing of drpr Leads to Muscle and Brain Degeneration in Adult Drosophila. American Journal of Pathology, 2014, 184, 2653-2661.	3.8	23
72	Reply. Muscle and Nerve, 2014, 50, 458-459.	2.2	0

#	Article	lF	Citations
73	Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology, 2014, 83, 810-817.	1.1	367
74	Childhood chronic inflammatory demyelinating polyradiculoneuropathy: Combined analysis of a large cohort and eleven published series. Neuromuscular Disorders, 2013, 23, 103-111.	0.6	62
75	Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscular Disorders, 2013, 23, 529-539.	0.6	79
76	Cysteine mutations cause defective tyrosine phosphorylation in MEGF10 myopathy. FEBS Letters, 2013, 587, 2952-2957.	2.8	16
77	Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2. Neuromuscular Disorders, 2013, 23, 975-980.	0.6	32
78	MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death and Differentiation, 2013, 20, 1194-1208.	11.2	140
79	A novel syndrome caused by the E410K amino acid substitution in the neuronal \hat{l}^2 -tubulin isotype 3. Brain, 2013, 136, 522-535.	7.6	112
80	Update on juvenile myasthenia gravis. Current Opinion in Pediatrics, 2013, 25, 694-700.	2.0	43
81	The New Frontier of Genetically Targeted Therapies for Muscle Disease. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1698-1702.	0.8	0
82	Clinical correlates of charcot–marie–tooth disease in patients with pes cavus deformities. Muscle and Nerve, 2013, 47, 488-492.	2.2	22
83	Beyond the Gowers sign: measuring outcomes in Duchenne muscular dystrophy. Muscle and Nerve, 2013, 48, 315-317.	2.2	3
84	Ethical issues in neurogenetic disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 118, 265-276.	1.8	5
85	Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Therapeutic Advances in Neurological Disorders, 2013, 6, 147-160.	3.5	24
86	Silencing of drpr leads to muscle and brain degeneration in adult Drosophila. FASEB Journal, 2013, 27, 873.14.	0.5	0
87	Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology, 2012, 79, 1889-1897.	1.1	207
88	Update on the Genetics of Limb Girdle Muscular Dystrophy. Seminars in Pediatric Neurology, 2012, 19, 211-218.	2.0	62
89	The Spectrum of Myotonic and Myopathic Disorders in a Pediatric Electromyography Laboratory Over 12 Years. Pediatric Neurology, 2012, 47, 97-100.	2.1	13
90	Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959.	2.5	115

#	Article	IF	CITATIONS
91	Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores. Neurogenetics, 2012, 13, 115-124.	1.4	68
92	Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatric Transplantation, 2012, 16, E296-300.	1.0	17
93	Presymptomatic and Early Symptomatic Genetic Testing. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 343-346.	0.8	1
94	Autoimmune Neuromuscular Disorders in Childhood. Current Treatment Options in Neurology, 2011, 13, 590-607.	1.8	24
95	Molecular diagnosis of hereditary inclusion body myopathy by linkage analysis and identification of a novel splice site mutation in GNE. BMC Medical Genetics, 2011, 12, 87.	2.1	13
96	Regulation of DMD pathology by an ankyrin-encoded miRNA. Skeletal Muscle, 2011, 1, 27.	4.2	81
97	The struggle to model muscular dystrophy. Muscle and Nerve, 2011, 44, 157-159.	2.2	1
98	Observational Study of Spinal Muscular Atrophy Type 2 and 3. Archives of Neurology, 2011, 68, 779.	4.5	142
99	Serum Transaminase Levels in Boys With Duchenne and Becker Muscular Dystrophy. Pediatrics, 2011, 127, e132-e136.	2.1	63
100	Efficient identification of novel mutations in patients with limb girdle muscular dystrophy. Neurogenetics, 2010, 11, 449-455.	1.4	15
101	Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. Muscle and Nerve, 2010, 41, 746-750.	2.2	21
102	Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder. Journal of Inherited Metabolic Disease, 2010, 33, 83-90.	3.6	37
103	Novel MPZ mutations and congenital hypomyelinating neuropathy. Neuromuscular Disorders, 2010, 20, 725-729.	0.6	14
104	Juvenile myasthenia gravis. Muscle and Nerve, 2009, 39, 423-431.	2.2	110
105	Pediatric monomelic amyotrophy: Evidence for poliomyelitis in vulnerable populations. Muscle and Nerve, 2009, 40, 860-863.	2.2	5
106	Congenital Myasthenic Syndrome With Episodic Apnea. Pediatric Neurology, 2009, 41, 42-45.	2.1	38
107	Mitochondrial fusion and function in Charcot–Marie–Tooth type 2A patient fibroblasts with mitofusin 2 mutations. Experimental Neurology, 2008, 211, 115-127.	4.1	88
108	A Case of Congenital Glycogen Storage Disease Type IV With a Novel GBE1 Mutation. Journal of Child Neurology, 2008, 23, 349-352.	1.4	19

#	Article	IF	CITATIONS
109	Child Neurology: Chronic inflammatory demyelinating polyradiculoneuropathy in children. Neurology, 2008, 71, e74-8.	1.1	22
110	Response of Motor Complications in Cockayne Syndrome to Carbidopa-Levodopa. Archives of Neurology, 2008, 65, 1117-21.	4.5	17
111	Distinctive patterns of microRNA expression in primary muscular disorders. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17016-17021.	7.1	458
112	Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics, 2007, 19, 675-679.	2.0	32
113	LGMD2I in a North American population. BMC Musculoskeletal Disorders, 2007, 8, 115.	1.9	29
114	Cardiac electrophysiological characteristics of the mdx 5cv mouse model of Duchenne muscular dystrophy. Journal of Interventional Cardiac Electrophysiology, 2007, 20, 1-7.	1.3	16
115	Pediatric Nerve Conduction Studies and EMG. , 2007, , 369-389.		15
116	Neuromuscular pathology in Vici syndrome. FASEB Journal, 2007, 21, A399.	0.5	0
117	Transcriptome-scale similarities between mouse and human skeletal muscles with normal and myopathic phenotypes. BMC Musculoskeletal Disorders, 2006, 7, 23.	1.9	28
118	Atypical presentations of spinal muscular atrophy type III (Kugelberg–Welander disease). Neuromuscular Disorders, 2006, 16, 492-494.	0.6	13
119	Involvement of superficial peroneal sensory nerve in common peroneal neuropathy. Muscle and Nerve, 2005, 31, 725-729.	2.2	30
120	Variations in gene expression among different types of human skeletal muscle. Muscle and Nerve, 2005, 32, 483-491.	2.2	28
121	The influence of muscle type and dystrophin deficiency on murine expression profiles. Mammalian Genome, 2005, 16, 739-748.	2.2	35
122	Transcriptional profile of postmortem skeletal muscle. Physiological Genomics, 2004, 16, 222-228.	2.3	38
123	Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle and Nerve, 2004, 29, 531-536.	2.2	37
124	Ambulatory foot temperature measurement: A new technique in polyneuropathy evaluation. Muscle and Nerve, 2003, 27, 737-742.	2.2	20
125	Diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita. Annals of Neurology, 2003, 54, 790-795.	5.3	31
126	Infantile Leukoencephalopathy Owing to Mitochondrial Enzyme Dysfunction. Journal of Child Neurology, 2002, 17, 421-428.	1.4	15

#	Article	IF	CITATIONS
127	Medial medullary injury during adenoidectomy. Journal of Pediatrics, 2001, 138, 772-774.	1.8	11
128	Lactic Acid Elevation in Extramitochondrial Childhood Neurodegenerative Diseases. Journal of Child Neurology, 2001, 16, 657-660.	1.4	29
129	A two-year-old girl with acute onset of seizures and progressive encephalopathy. Current Opinion in Pediatrics, 1997, 9, 558-564.	2.0	O